CN106831594A - 可乐定双羟萘酸盐及其制备方法 - Google Patents
可乐定双羟萘酸盐及其制备方法 Download PDFInfo
- Publication number
- CN106831594A CN106831594A CN201710032848.6A CN201710032848A CN106831594A CN 106831594 A CN106831594 A CN 106831594A CN 201710032848 A CN201710032848 A CN 201710032848A CN 106831594 A CN106831594 A CN 106831594A
- Authority
- CN
- China
- Prior art keywords
- clonidine
- embonate
- crystal formation
- salt
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002896 clonidine Drugs 0.000 title claims abstract description 150
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 title claims abstract description 149
- 229950005627 embonate Drugs 0.000 title claims abstract description 113
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000013078 crystal Substances 0.000 claims abstract description 124
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 107
- 239000002904 solvent Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 9
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims 3
- 238000005755 formation reaction Methods 0.000 abstract description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 19
- 229960002925 clonidine hydrochloride Drugs 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 16
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000005507 spraying Methods 0.000 abstract description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 17
- 238000001757 thermogravimetry curve Methods 0.000 description 13
- -1 organic acid Salt Chemical class 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 230000003578 releasing effect Effects 0.000 description 8
- 238000000967 suction filtration Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical class [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical class C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710032848.6A CN106831594B (zh) | 2017-01-18 | 2017-01-18 | 可乐定双羟萘酸盐及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710032848.6A CN106831594B (zh) | 2017-01-18 | 2017-01-18 | 可乐定双羟萘酸盐及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106831594A true CN106831594A (zh) | 2017-06-13 |
CN106831594B CN106831594B (zh) | 2018-02-02 |
Family
ID=59124896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710032848.6A Active CN106831594B (zh) | 2017-01-18 | 2017-01-18 | 可乐定双羟萘酸盐及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106831594B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110003195A (zh) * | 2019-05-21 | 2019-07-12 | 湖北中医药大学 | 鲁拉西酮晶体及其制备方法和在注射给药系统中的应用 |
CN114195740A (zh) * | 2020-08-26 | 2022-03-18 | 上海博志研新药物技术有限公司 | 卡利拉嗪药用盐及其晶型、制备方法和应用 |
WO2023160583A1 (zh) * | 2022-02-22 | 2023-08-31 | 上海云晟研新生物科技有限公司 | 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1121719A (zh) * | 1993-04-28 | 1996-05-01 | 詹森药业有限公司 | 瑞斯哌利酮双羟萘酸盐 |
CN1678316A (zh) * | 2002-08-22 | 2005-10-05 | 普雷斯特维克药物公司 | 哌淀-2,6-二酮双羟萘酸盐及其在治疗与紧张有关的情感障碍中的应用 |
CN104039765A (zh) * | 2011-11-29 | 2014-09-10 | 顾自强 | 多奈哌齐双羟萘酸盐、制备方法及其应用 |
CN105919943A (zh) * | 2016-04-26 | 2016-09-07 | 青岛正大海尔制药有限公司 | 一种盐酸可乐定控释颗粒及其制备方法 |
-
2017
- 2017-01-18 CN CN201710032848.6A patent/CN106831594B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1121719A (zh) * | 1993-04-28 | 1996-05-01 | 詹森药业有限公司 | 瑞斯哌利酮双羟萘酸盐 |
CN1678316A (zh) * | 2002-08-22 | 2005-10-05 | 普雷斯特维克药物公司 | 哌淀-2,6-二酮双羟萘酸盐及其在治疗与紧张有关的情感障碍中的应用 |
CN104039765A (zh) * | 2011-11-29 | 2014-09-10 | 顾自强 | 多奈哌齐双羟萘酸盐、制备方法及其应用 |
CN105919943A (zh) * | 2016-04-26 | 2016-09-07 | 青岛正大海尔制药有限公司 | 一种盐酸可乐定控释颗粒及其制备方法 |
Non-Patent Citations (1)
Title |
---|
宁保明: "《化学药品对照品图谱集--热分析》", 31 August 2014 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110003195A (zh) * | 2019-05-21 | 2019-07-12 | 湖北中医药大学 | 鲁拉西酮晶体及其制备方法和在注射给药系统中的应用 |
CN110003195B (zh) * | 2019-05-21 | 2020-05-26 | 湖北中医药大学 | 鲁拉西酮晶体及其制备方法和在注射给药系统中的应用 |
CN114195740A (zh) * | 2020-08-26 | 2022-03-18 | 上海博志研新药物技术有限公司 | 卡利拉嗪药用盐及其晶型、制备方法和应用 |
CN114195740B (zh) * | 2020-08-26 | 2023-11-14 | 上海云晟研新生物科技有限公司 | 卡利拉嗪药用盐及其晶型、制备方法和应用 |
WO2023160583A1 (zh) * | 2022-02-22 | 2023-08-31 | 上海云晟研新生物科技有限公司 | 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106831594B (zh) | 2018-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106831594B (zh) | 可乐定双羟萘酸盐及其制备方法 | |
CN102702008B (zh) | 阿戈美拉汀硫酸复合物及其制备方法 | |
CN107428727A (zh) | 来那替尼马来酸盐的新晶型及其制备方法 | |
CN110483486A (zh) | 一种奥西替尼酮咯酸盐晶型及其制备方法 | |
CN108794555A (zh) | 一种炔雌醇药物共晶及其制备方法 | |
WO2022171044A1 (zh) | 一种氧氮杂螺环化合物、其盐型及其晶型 | |
CN102702041B (zh) | 阿戈美拉汀苯磺酸类复合物及其制备方法 | |
BRPI0308706B1 (pt) | Hidrato de darifenacina, e processo para sua preparação | |
CN105111127B (zh) | 阿普斯特无定形及其制备方法 | |
CN109400598A (zh) | 盐酸小檗碱与乳酸共晶、其制备方法和应用 | |
CN113105389A (zh) | 一种阿立哌唑药物共晶及其制备方法 | |
CN110156793B (zh) | 瑞博西尼单琥珀酸盐新晶型及制备方法 | |
KR101406736B1 (ko) | 아고멜라틴 히드로브로마이드 히드레이트 및 이의 제법 | |
CN109912510A (zh) | 一种替硝唑-香草酸药物共晶及其制备方法 | |
WO2020147838A1 (zh) | 一种egfr抑制剂的盐、晶型及其制备方法 | |
Blokhina et al. | New diclofenac choline hydrate salt: Synthesis, characterization and solubility | |
CN113402458A (zh) | 一种恩诺沙星共晶及其制备方法 | |
RU2456291C2 (ru) | Безводные кристаллические соли винфлунина, способ их получения и их применение в качестве лекарства, и способ очистки винфлунина | |
WO2013170738A1 (zh) | 阿戈美拉汀酸根复合物及其制备方法和用途 | |
CN114149426B (zh) | 帕博西尼药物共晶及其制备方法 | |
CN110177779A (zh) | 一种病毒蛋白抑制剂药物vx-787的晶型及其制备方法和用途 | |
WO2024037532A1 (zh) | 一种噻吩并嘧啶酮衍生物的盐型及晶型 | |
CN112552367B (zh) | 一种地高辛衍生物及其制备方法 | |
WO2022199708A1 (zh) | 卢美哌隆药用盐、制备方法、含其的药物组合物及应用 | |
CN114685466B (zh) | 一种阿昔替尼共晶盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB03 | Change of inventor or designer information |
Inventor after: Gu Ziqiang Inventor after: Zhu Haijian Inventor after: Xu Liangliang Inventor after: Jie Congneng Inventor after: Cai Linhui Inventor before: Zhu Haijian Inventor before: Xu Liangliang Inventor before: Jie Congneng Inventor before: Cai Linhui Inventor before: Gu Ziqiang |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190307 Address after: Unit 1102, 120 Xinyuan Road, Haicang District, Xiamen City, Fujian Province Co-patentee after: Power Pharmaceutical (Xiamen) Co., Ltd. Patentee after: Dynamic bio Pharmaceutical Technology (Xiamen) Co., Ltd. Address before: Unit 1102, 120 Xinyuan Road, Haicang District, Xiamen City, Fujian Province Patentee before: Dynamic bio Pharmaceutical Technology (Xiamen) Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Unit 1102, 120 Xinyuan Road, Haicang District, Xiamen City, Fujian Province Patentee after: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. Patentee after: Lipin Pharmaceutical (Xiamen) Co.,Ltd. Address before: Unit 1102, 120 Xinyuan Road, Haicang District, Xiamen City, Fujian Province Patentee before: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. Patentee before: Lipin Pharmaceutical (Xiamen) Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: Unit 01-1, 8th floor, building B14, 2076 wengjiao West Road, Haicang District, Xiamen City, Fujian Province, 361000 Patentee after: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. Patentee after: Lipin Pharmaceutical (Xiamen) Co.,Ltd. Address before: Unit 1102, 120 Xinyuan Road, Haicang District, Xiamen City, Fujian Province Patentee before: RALLY BIOMEDICAL TECHNOLOGY (XIAMEN) Co.,Ltd. Patentee before: Lipin Pharmaceutical (Xiamen) Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |